Superworth

McKesson price to free cash flow MCK

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026
18.2×
10-year median
10.8×
Against its 10-year history
90th
percentile: 0 is its lowest day, 100 its highest
10-year range
4.8× to 46.0×
Peer median
19.9×

McKesson's price to free cash flow is 18.2× as of Oct 23, 2026.

That is above its ten-year median of 10.8×, higher than on 90% of days in the last ten years.

Over that time it ranged from 4.8× in Apr 2017 to 46.0× in May 2025.

The median for 10 healthcare stocks of a similar size is 19.9×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far18.2×10.0×18.3×
202516.1×13.8×46.0×
202415.9×14.1×22.9×
202313.6×10.7×13.8×
202213.1×8.8×13.8×
20218.8×5.0×9.2×
20206.8×5.8×9.3×
20197.9×5.2×9.6×
20187.4×6.8×14.1×
201711.9×4.8×12.4×
20166.5×5.7×19.5×
201511.8×10.7×23.4×
201422.6×14.4×22.9×
201314.5×8.0×19.7×
201212.4×7.0×12.7×
20117.1×7.0×13.7×
201013.0×8.1×13.1×

Against its peers

Companies in Healthcare nearest McKesson's size, closest first, today.

CompanyPrice to free cash flow
MCKMcKesson18.2×
SYKStryker25.1×
CVSCVS Health10.2×
MDTMedtronic19.9×
BMYBristol-Myers Squibb11.0×
VRTXVertex Pharmaceuticals35.0×
HCAHCA Healthcare16.9×
ELVElevance Health15.2×
ISRGIntuitive Surgicaln/m
DHRDanaher29.6×
REGNRegeneron Pharmaceuticals22.0×
Peer median19.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on McKesson

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.